B6-hB7-H3 (hCD276) Mouse
Product Name
B6-hB7-H3 (hCD276) Mouse
Product ID
C001716
Strain Name
C57BL/6NCya-Cd276tm1(hCD276)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-hB7-H3 (hCD276) Mouse (Catalog C001716) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
CD276
Gene Alias
B7H3, B7-H3, B7RP-2, 4Ig-B7-H3
NCBI ID
Chromosome
Chr 15 (Human)
MGI ID
Datasheet
Strain Description
The CD276 gene, also known as B7-H3, encodes a type I transmembrane glycoprotein that belongs to the B7 family of immune checkpoint regulators [1]. Characterized by its limited expression in most normal human tissues, CD276 is frequently observed to be upregulated in a diverse range of human malignancies and within their associated tumor microenvironments, as well as on specific immune cell populations including antigen-presenting cells [2]. The encoded protein functions as a context-dependent modulator of T cell responses, exhibiting both co-stimulatory and co-inhibitory activities that influence T cell activation, proliferation, and cytokine production [3]. Expressed on tumor cells, antigen-presenting cells, and endothelial cells within the tumor vasculature, aberrant expression of CD276 has been strongly implicated in promoting tumor progression, metastasis, and the evasion of anti-tumor immunity, thereby positioning it as a compelling target for therapeutic intervention in oncology [4].
The B6-hB7-H3 (hCD276) mouse is a humanized model constructed by replacing the sequence of the mouse Cd276 endogenous extracellular domain in situ with the corresponding extracellular domain from the human CD276. The murine signal peptide was preserved. The B6-hB7-H3 (hCD276) mice can be used for the study of the pathogenesis of various cancers such as breast cancer, glioblastoma, and non-small cell lung cancer, as well as for CD276-targeted drug development.
Reference
Zhou WT, Jin WL. B7-H3/CD276: An Emerging Cancer Immunotherapy. Front Immunol. 2021 Jul 19;12:701006.
Liu S, Liang J, Liu Z, Zhang C, Wang Y, Watson AH, Zhou C, Zhang F, Wu K, Zhang F, Lu Y, Wang X. The Role of CD276 in Cancers. Front Oncol. 2021 Mar 26;11:654684.
Xiong G, Chen Z, Liu Q, Peng F, Zhang C, Cheng M, Ling R, Chen S, Liang Y, Chen D, Zhou Q. CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs. J Immunother Cancer. 2024 May 9;12(5):e008662.
Getu AA, Tigabu A, Zhou M, Lu J, Fodstad Ø, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023 Mar 2;22(1):43.
Strain Strategy
Figure 1. Gene editing strategy of B6-hB7-H3 (hCD276) Mice. The mouse Cd276 endogenous extracellular domain was replaced with the human CD276 extracellular domain. The murine signal peptide was preserved.
Application Area
CD276-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of various solid tumors (such as breast cancer, glioblastoma, and non-small cell lung cancer) and other cancers;
Research on cancer immunotherapy.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
